Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›SNY›Insulin glargine · SAFIR

Insulin glargine · SAFIR

Ensayo de Sanofi en Diabetes mellitus tipo 2.

Fase
Fase 4
Estado
Completado
Participantes
480
previstos
Fin del objetivo primario
mar 2004
fecha real

Título oficial en el registro (en inglés): Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en oct 2003.

De principio a fin

  1. Empieza el ensayo (oct 2003)
  2. Lectura de resultados mar 2004 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Frecuencia de sujetos con hipoglucemia detectada convencionalmente

Cómo lo describe el promotor

En el documentoEn inglés, del registroPrimary objective: Difference in frequency of subjects with conventionally detected hypoglycemia by the subject [at least one measurement smaller/equal 60mg/dl documented in the 8-point profile in the case record form (CRF) or documentation of symptomatic hypoglycemia in the CRF through Visits 8/9] compared to CGMS detected blood glucose values smaller/equal 60mg/dl during CGMS measurements (at least one measurement through Visits 8/9) after eight weeks of treatment with insulin glargine. Secondary objective: Secondary study objectives were to investigate the safety and efficacy of a treatment change to insulin glargine in ICT treated subjects in terms of: * Percentage of blood glucose measurements(CGMS data)smaller/equal 60mg/dl [3.3 mmol/l]. * Percentage of nocturnal blood glucose measurements(CGMS data)smaller/equal 60mg/dl[3.3 mmol/l]. * Percentage of daytime blood glucose measurements(CGMS data)smaller/equal 60mg/dl[3.3 mmol/l]. * Area under the curve (AUC smaller/equal 60)and time(t smaller/equal 60)for blood glucose smaller/equal 60mg/dl[3.3mmol/l], area under the curve (AUC greater/equal 180)and time (t greater/equal 180) for blood glucose greater/equal 180mg/dl[10.0mmol/l]. * Area under the curve (AUC smaller/equal 60)and time(t smaller/equal 60)for blood glucose smaller/equal 60mg/dl[3.3mmol/l]during the day (AUC 06.00am - 10.00pm)and during the night(AUC 10.00pm - 06.00am). * Area under the curve (AUC greater/equal 180)and time(t greater/equal 180)for blood glucose greater/equal 180mg/dl[10.0mmol/l]during the day (AUC 06.00am - 10.00pm)and during the night(AUC 10.00pm - 06.00am). * Frequency of subjects with nocturnal blood glucose value smaller/equal 60mg/dl[3.3 mmol/l]. * Frequency of subjects with asymptomatic nocturnal blood glucose smaller/equal 60mg/dl[3.3 mmol/l]. * Frequency of subjects with symptomatic nocturnal blood glucose smaller/equal 60mg/dl [3.3 mmol/l]. * Frequency of subjects with daytime blood glucose smaller/equal 60mg/dl [3.3 mmol/l]. * Frequency of subjects with asymptomatic daytime blood glucose smaller/equal 60mg/dl[3.3 mmol/l]. * Frequency of subjects with symptomatic daytime blood glucose smaller/equal 60mg/dl[3.3 mmol/l]. * Frequency of subjects with hyperglycemic blood glucose(greater/equal 180mg/dl,[10.0mmol/l]). * Frequency of subjects with symptomatic hypoglycemia(smaller/equal 60mg/dl [3.3mmol]). * Frequency of subjects with severe hypoglycemia(smaller/equal 36mg/dl [2.0mmol/l]). * Blood glucose values of 8-point profiles. * Mean daytime \& mean nocturnal blood glucose of 8-point-profiles. * HbA1c. * Fasting blood glucose (FBG). * Dose of insulin. * Adjustment of insulin. * Body weight, body mass index.

Sigue a SNY y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Más ensayos de SNY

EnsayoFaseEstadoLectura de resultados
Avalglucosidase alfa · Mini-COMETFase 2En marcha, sin reclutarsep 2019 (real)
Yellow fever vaccineFase 2En marcha, sin reclutarmay 2022 (real)
Yellow fever vaccine · VYF02Fase 2En marcha, sin reclutarjun 2022 (real)
SAR441344 IVFase 2En marcha, sin reclutarsep 2022 (real)
Meningococcal PolysaccharideFase 3En marcha, sin reclutarmar 2023 (real)
rilzabrutinib · LUMINA 2Fase 2En marcha, sin reclutarmay 2024 (real)

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00354939), actualizada en ago 2010.